The release of the first overactive bladder (OAB) guidelines was associated with an increase in OAB diagnoses, a decrease in anticholinergic medication use, and a rise in beta-3 agonist use, according ...

UTUC affects 1-2 per 100,000 people in the U.S., representing 6% of urothelial carcinoma cases, with symptoms like hematuria and urinary obstruction. Treatment strategies for UTUC depend on tumor ...

SunRISe-5 and MoonRISe-1 trials investigate TAR-200 and TAR-210 in non-muscle-invasive bladder cancer, focusing on disease-free survival and recurrence prevention. ARASTEP trial evaluates darolutamide ...

Biomarkers are vital in diagnosing and managing urological diseases, with PSA testing crucial for early prostate cancer detection. State legislation is increasingly mandating insurance coverage for ...

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer. 177 Lu-PSMA-617 (Pluvicto) was approved by the FDA in March 2022 for ...

The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of overactive bladder comes with several important considerations. The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of ...

Video content above is prompted by the following: Evolution of BPH Treatment Outcomes Dr Christopher Kelly discusses the evolution of patient outcomes with different benign prostatic hyperplasia (BPH) ...

We preview several noteworthy P2 presentations in the urologic oncology space. The American Urological Association (AUA) will try its luck in Las Vegas, Nevada for its 2025 annual meeting. Taking ...

“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM. There are ...

“Like any disease state, you want to make sure you have the right diagnosis; otherwise, you're not going to have a successful treatment plan," says Karyn S. Eilber, MD. The landscape of treatment for ...

Nadofaragene firadenovec achieved a 75% complete response rate at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC. The therapy demonstrated a favorable safety profile, with no ...

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey. Receiving an initial diagnosis of renal cell carcinoma (RCC) is often an overwhelming ...